# A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults

> **NCT05011526** · PHASE3 · COMPLETED · sponsor: **Medigen Vaccine Biologics Corp.** · enrollment: 1030 (actual)

## Conditions studied

- Covid19 Vaccine

## Interventions

- **BIOLOGICAL:** MVC-COV1901
- **BIOLOGICAL:** AZD1222

## Key facts

- **NCT ID:** NCT05011526
- **Lead sponsor:** Medigen Vaccine Biologics Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-08
- **Primary completion:** 2021-12-28
- **Final completion:** 2022-05-21
- **Target enrollment:** 1030 (ACTUAL)
- **Last updated:** 2022-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05011526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05011526, "A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05011526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*